ORIGINAL RESEARCH article

Front. Immunol.

Sec. Parasite Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1622435

This article is part of the Research TopicDissecting malaria protective immunity: acquired by natural infection and/or vaccinationView all 9 articles

Exploring the P. falciparum antigens associated with reduced risk of malaria in pregnancy

Provisionally accepted
  • 1Mount Kenya University, Thika, Kenya
  • 2Ehime University, Matsuyama, Japan

The final, formatted version of the article will be published soon.

Plasmodium falciparum infection in pregnancy leads to substantial maternal and infant morbidity and mortality. Such an infection may result in placental malaria (PM) due to P. falciparum-infected red blood cells adhering to the placenta via parasite-derived ligands. Despite the risk of infection being the same for women of all gravidities, the risk of poor birth outcomes is highest in primigravida women as they lack protective antibodies against placental malaria-associated parasites. Thus, understanding how specific P. falciparum antigens interact with the host’s immune system during the first and subsequent pregnancies may provide insights into the immunopathology of malaria and guide vaccine target prioritization. In this study, we assessed human antibody responses to 698 P. falciparum recombinant antigens derived from different antigen families among Kenyan primigravida and multigravida women. Consistent with existing literature, we observed high immunoreactivity across the different antigen families, with the number of antigens identified by sera from pregnant women increasing with gravidity. Antibody response analysis selected 3 antigens: PF3D7_1301800 (SURFIN 13.1), PF3D7_0424400 (SURFIN 4.2), and PF3D7_1252100 (rhoptry neck antigen 3 domain) as statistically significant in multigravida. While all five VAR2CSA domains were immunoreactive with seroprevalence of 42 - 62% and correlated with the selected antigens, which suggests co-acquisition, none had statistical significance in association with gravidity. Thus, although further characterization of the selected antigens will be required, this study may provide insights into targets that could be prioritized for vaccine development to reduce risks associated with malaria in pregnancy.

Keywords: Malaria in pregnancy, placental malaria. gravida, Antibodies, Immunity, bloodstage proteins

Received: 03 May 2025; Accepted: 24 Jun 2025.

Copyright: © 2025 Mwai, Musundi, Waweru, Nagaoka, Tsuboi, Takashima, Gitaka and Kanoi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Bernard N. Kanoi, Mount Kenya University, Thika, Kenya

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.